Výsledky vyhľadávania - "HER2-low"

Patterns of treatment and outcomes of patients with metastatic HER2-low breast cancer treated with CDK4/6 inhibitors and hormone therapy

Autori: Federico Sottotetti Barbara Tagliaferri Gianpiero Rizzo a ďalší

Zdroj: Drugs Context
Drugs in Context, Vol 14, Pp 1-14 (2025)

Predmety: her2-low, palbociclib, abemaciclib, metastatic breast cancer, Therapeutics. Pharmacology, RM1-950, antibody–drug conjugates, ribociclib, therapeutic strategies, Original Research

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/40385566
https://doaj.org/article/7f8d11e5ffa5461dbee63bdcc932132d

Cáncer de mama HER2-bajo: una nueva era en terapias dirigidas

Autori: Benjamín Walbaum, MD Francisco Acevedo, MD, MSc Lidia Medina, RN a ďalší

Zdroj: Revista Médica Clínica Las Condes, Vol 36, Iss 3, Pp 210-220 (2025)

Predmety: Antibody-Drug Conjugate, HER2Positive, Medicine, HER2-Low, Breast Neoplasm

Prístupová URL adresa: https://doaj.org/article/b0a49888bd9340d2a8772530beae8e9c

Trastuzumab deruxtecan for the late lines of treatment for HER2-low metastatic breast cancer: a clinical case

Autori: R. A. Murashko S. V. Sharov E. P. Chashnikova

Zdroj: Опухоли женской репродуктивной системы, Vol 20, Iss 4, Pp 95-100 (2025)

Predmety: trastuzumab deruxtecan, breast cancer, her2-low, breast cancer with her2-low expression, RG1-991, metastasis, Gynecology and obstetrics, late lines of therapy, liver metastases

Prístupová URL adresa: https://doaj.org/article/b9a5acc08e4447a6a38e9d1531a986f7

Changes in HER2low and HER2-ultralow status in 47 advanced breast carcinoma core biopsies, matching surgical specimens, and their distant metastases assessed by conventional light microscopy, digital pathology, and artificial intelligence

Autori: Kovács, Anikó Klint, Leif Linderholm, Barbro a ďalší

Zdroj: Breast Cancer Research and Treatment. 213(3):397-408

Predmety: Cancer and Oncology, Cancer och onkologi, Artificial Intelligence, Changes in HER2-Low status, HER2-Low breast cancer, HER2-Null breast cancer, HER2-Ultralow breast cancer

Prístupová URL adresa: https://gup.ub.gu.se/publication/352549

Identification and validation of a prognostic model for HER2-low breast cancer based on unfolded protein response-related genes

Autori: Yanjiao Zhao Yuanyuan Gao Hui Yan a ďalší

Zdroj: Discover Oncology, Vol 16, Iss 1, Pp 1-14 (2025)

Predmety: HER2-low breast cancer, Unfolded protein response related genes, Risk score, Prognosis, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

Popis súboru: electronic resource

Relation: https://doaj.org/toc/2730-6011

Prístupová URL adresa: https://doaj.org/article/fdaa1b21ef474539b22b21d885095728

Differences in Sentinel lymph node biopsy outcomes and prognosis between HER2-low and HER2-zero breast cancer

Autori: Koji Takada Shinichiro Kashiwagi Mariko Nishikawa a ďalší

Zdroj: BMC Cancer, Vol 25, Iss 1, Pp 1-11 (2025)

Predmety: Breast cancer, HER2-low, Prognosis, Sentinel lymph node, Axillary lymph node dissection, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

Popis súboru: electronic resource

Relation: https://doaj.org/toc/1471-2407

Prístupová URL adresa: https://doaj.org/article/a54d7ad2e8d04a8c9f2327b7c755b313

Analysis of clinicopathological features and clinical significance in 25 cases of mammary adenoid cystic carcinoma

Autori: Xiaoyan Xu Shasha Yu Wei Qu a ďalší

Zdroj: BMC Women's Health, Vol 25, Iss 1, Pp 1-8 (2025)

Predmety: Mammary adenoid cystic carcinoma(AdCC), Clinicopathological features, Gene alterations, Prognosis, HER2-low expression, Gynecology and obstetrics, RG1-991, Public aspects of medicine, RA1-1270

Popis súboru: electronic resource

Relation: https://doaj.org/toc/1472-6874

Prístupová URL adresa: https://doaj.org/article/9606e1949cec42a39daf90ad172272bb

Concordance of HER2-low scoring in breast carcinomas among pathologists

Autori: Tomić, Snježana Ivković, Tatjana Kapicl Periša, Marija Milković a ďalší

Zdroj: Sci Rep

Predmety: Breast cancer, Trastuzumab Deruxtekan, HER2-low, Breast cancer, HER2-low, Trastuzumab-deruxtecan, Article

Popis súboru: application/pdf

Prístupová URL adresa: https://urn.nsk.hr/urn:nbn:hr:184:609819
https://doi.org/10.1038/s41598-025-09839-6

Topological Data Analysis Reveals a Subgroup of Luminal B Breast Cancer

Autori: Zahra Rostami David Fooshee Gunnar Carlsson a ďalší

Zdroj: IEEE Open J Eng Med Biol
IEEE Open Journal of Engineering in Medicine and Biology, Vol 6, Pp 465-471 (2025)

Predmety: Topological data analysis (TDA), machine learning, breast cancer (BC), Computer applications to medicine. Medical informatics, R858-859.7, Medical technology, HER2-low breast cancer, R855-855.5, Article, dimensionality reduction

Prístupová URL adresa: https://doaj.org/article/b81d736b113f4433ad73113ad6982271

Survival outcomes for HER2-low breast cancer: Danish national data

Autori: Michael Sode Kåre Nielsen Maj-Britt Jensen a ďalší

Zdroj: Acta Oncol
Acta Oncologica, Vol 63, Iss 1 (2024)
Sode, M, Nielsen, K, Jensen, M-B, Berg, T, Knoop, A, Ejlertsen, B & Lænkholm, A V 2024, ' Survival outcomes for HER2-low breast cancer : Danish national data ', Acta oncologica (Stockholm, Sweden), vol. 63, pp. 878-886 . https://doi.org/10.2340/1651-226X.2024.41280

Predmety: Adult, Aged, 80 and over, Receptor, ErbB-2, Denmark, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, HER2-low breast cancer, Breast Neoplasms, Survival analysis, Middle Aged, Prognosis, Receptors, Estrogen, HER2, Biomarkers, Tumor, Humans, Original Article, Female, HER2-low prognosis, DBCG, Neoplasm Recurrence, Local, RC254-282, Aged, Retrospective Studies

Popis súboru: application/pdf

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/39543845
https://doaj.org/article/23de7ff8c85c46a18a7018b883ff9989
https://curis.ku.dk/ws/files/413620516/AO41280.pdf

Prediction of neoadjuvant chemotherapy efficacy in patients with HER2-low breast cancer based on ultrasound radiomics

Autori: Qing Peng Ziyao Ji Nan Xu a ďalší

Zdroj: Cancer Imaging, Vol 25, Iss 1, Pp 1-18 (2025)

Predmety: HER2-low breast cancer, Neoadjuvant chemotherapy, Ultrasound, Radiomics, Machine learning, Medical physics. Medical radiology. Nuclear medicine, R895-920, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

Popis súboru: electronic resource

Relation: https://doaj.org/toc/1470-7330

Prístupová URL adresa: https://doaj.org/article/269efa58efab4b3ea499de10091d4d74

Differences in survival outcomes between HER2-low and HER2-zero breast cancer across heterogeneous HR expression patterns: a real-world study

Autori: Yi Zeng Pengfei Qian Guanhong Li a ďalší

Zdroj: World Journal of Surgical Oncology, Vol 23, Iss 1, Pp 1-17 (2025)

Predmety: Breast cancer, HER2-low, Estrogen receptor, Progesterone receptor, Surgery, RD1-811, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

Popis súboru: electronic resource

Relation: https://doaj.org/toc/1477-7819

Prístupová URL adresa: https://doaj.org/article/f412976ebbbc45b0a5ac58f6c384d88b

Performance of a HER2 testing algorithm tailored for urothelial bladder cancer: A Bi-centre study

Autori: Aoling Huang Yizhi Zhao Feng Guan a ďalší

Zdroj: Comput Struct Biotechnol J
Computational and Structural Biotechnology Journal, Vol 26, Iss, Pp 40-50 (2024)

Predmety: 0301 basic medicine, Artificial intelligence, 03 medical and health sciences, 0302 clinical medicine, Bladder cancer, HER2-low, Heterogeneity, TP248.13-248.65, Biotechnology, Research Article

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/39469445
https://doaj.org/article/af9ec4b1370342b5a6af974f714fbbb7

Cost-Effectiveness of Trastuzumab Deruxtecan in Patients with Unresectable or Metastatic HER2-Low Breast Cancer Who Have Received Prior Chemotherapy

Autori: Jeroen Hendrikus Jacobus Paulissen Alexander Victor van Schoonhoven Emma Olin a ďalší

Zdroj: Adv Ther

Predmety: Immunoconjugates, Receptor, ErbB-2, Cost-Benefit Analysis, Denmark, Breast Neoplasms, Trastuzumab, Middle Aged, Metastatic breast cancer, Antineoplastic Agents, Immunological, Humans, Cost-effectiveness, Trastuzumab deruxtecan, Female, Camptothecin, HER2-low, Quality-Adjusted Life Years, Neoplasm Metastasis, Original Research

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/39531128
https://research.rug.nl/en/publications/051ff833-b271-41a0-84a0-ea313b7b3688
https://doi.org/10.1007/s12325-024-03033-2
https://hdl.handle.net/11370/051ff833-b271-41a0-84a0-ea313b7b3688

Immunomorphological specifcity of HER2-low breast cancer

Autori: I. V. Mikhailov E. R. Eremeeva A. A. Glazkov a ďalší

Zdroj: Сибирский онкологический журнал, Vol 23, Iss 5, Pp 47-58 (2024)

Predmety: 0301 basic medicine, 03 medical and health sciences, breast cancer, 0302 clinical medicine, tumor-associated macrophages, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, negative her2-neu status, perineural invasion, her2-low status, RC254-282

Prístupová URL adresa: https://doaj.org/article/4544246363fa44b1a89e60192cdf70fd

Unfavorable Prognostic Impact of HER2 2+/FISH-Negativity in Older Patients with HER2-Negative and High-Risk Breast Cancer

Autori: Hao Wang Miao Yu Meihua Chen a ďalší

Zdroj: Breast Cancer (Dove Med Press)
Breast Cancer: Targets and Therapy, Vol Volume 16, Pp 785-793 (2024)

Predmety: 0301 basic medicine, 03 medical and health sciences, breast cancer, her2-low, her2 2+, 0302 clinical medicine, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, prognosis, older patients, RC254-282, Original Research

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/39588273
https://doaj.org/article/f03933e6f7f543778a50caaad066c360

Prise en charge du cancer du sein triple-négatif

Autori: Dalenc, Florence Poumeaud, François

Zdroj: Innovations & Thérapeutiques en Oncologie. 2024, Volume 10(N° Supp 2), p. 16-22.

Dostupnosť: https://stm.cairn.info/revue-innovations-et-therapeutiques-en-oncologie-2024-HS2-page-16?lang=fr

A Nationwide Study on HER2-Low Breast Cancer in South Korea: Its Incidence of 2022 Real World Data and the Importance of Immunohistochemical Staining Protocols

Autori: Min Chong Kim Eun Yoon Cho So Yeon Park a ďalší

Prispievatelia: Min Chong Kim Eun Yoon Cho So Yeon Park a ďalší

Zdroj: Cancer Res Treat

Predmety: Adult, Aged, 80 and over, Receptor, ErbB-2, Incidence, Breast Neoplasms, Middle Aged, Immunohistochemistry, HER2-testing, Republic of Korea, Biomarkers, Tumor, Humans, Original Article, Female, HER2-low, Breast neoplasms, Aged

Popis súboru: application/octet-stream

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/38453273

Improved Prognosis in HER2-Low Breast Cancer Patients with Reduced Ki67 Index After Neoadjuvant Chemotherapy: A Multi-Center Retrospective Study

Autori: Man Huang Yudi Jin Mengyuan Wang a ďalší

Zdroj: Breast Cancer (Dove Med Press)
Breast Cancer: Targets and Therapy, Vol Volume 16, Pp 667-678 (2024)

Predmety: ki67 index, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, her2-low breast cancer, prognosis, survival, RC254-282, neoadjuvant chemotherapy, Original Research

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/39403364
https://doaj.org/article/8d83ddca3ce04f8994588dd14d24ddb9

Multiparametric quantitative MRI combining SyMRI and MUSE-DWI for noninvasive stratification of HER2 status in breast cancer

Autori: Kui Yang Wei Zhang Hao Zheng a ďalší

Zdroj: Frontiers in Oncology, Vol 15 (2025)

Predmety: breast cancer, HER2, HER2-low, synthetic MRI (SyMRI), MUSE-DWI, multiparametric MRI, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

Popis súboru: electronic resource

Relation: https://www.frontiersin.org/articles/10.3389/fonc.2025.1709170/full; https://doaj.org/toc/2234-943X

Prístupová URL adresa: https://doaj.org/article/a04f95d9c5ff49de8b62089abf6df149